Heart Failure & SGLT2is: The New Pillar in Care - Resources

The goal of this page is to assemble the latest resources on the scientific developments in guideline-directed medical therapy for HF patients and provide practical guidance for SGLT2i use. This page has been curated with content focused on this topic and will be updated to include new developments as they are published.

• 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
• Heart Failure: Guideline For Management - ACC Hub
• Dr. Biykem Bozkurt Highlights Heart Failure Guideline’s Key Points
• 2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives
• Heart Failure Guidelines Toolkit - AHA Tool
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
• 2021 ESC Guidelines for Acute and Chronic Heart Failure: Key Points

• Management of Heart Failure Guideline Hub
• Rise Above Heart Failure Toolkit for Health Care Professionals
• Get With The Guidelines® - Heart Failure Clinical Tools
• TreatHF App
• SGLT2i Pocket Guide and Infographic - New!

• Don't Delay – Starting Empagliflozin During Acute Heart Failure Hospitalization
• The Emperor Finally Has Clothes! Insights from EMPEROR Preserved
• Beyond Diabetes: The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction
• Empagliflozin in Heart Failure with Preserved Ejection Fraction: A Worthy Opponent Against a Formidable Foe
• EMPEROR-Reduced Analysis: Empagliflozin Joins Dapagliflozin in Benefiting Heart Patients with and without Diabetes
• Shifting the Diabetes Management Model: Combination of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Confers Added Cardioprotective Benefits

• Heart Failure - CardioSmart Topic
• What is Heart Failure? - Infographic
• Turning Heart Failure Into Heart Success - Infographic
• Heart Failure Tools and Resources
• What is Heart Failure? - Article
• Heart Failure Questions to Ask Your Doctor
• SGLT2 Inhibitors for Heart Failure: What You Need to Know - Handout
• Tips for Starting an SGLT2 Inhibitor to Treat Your Heart Failure - Handout & Worksheet
• 8 Common Questions about SGLT2 Inhibitors - Handout

• Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER I November 9, 2022
• Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure I November 8, 2022
• SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure I October 4, 2022
• Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction I October 4, 2022
• Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction A Participant-Level Pooled Analysis of DAPA-HF and DELIVER I October 3, 2022
• Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age I July 5, 2022
• Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects I June 1, 2022
• Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial I March 1, 2022
• In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction I November 16, 2021
• Empagliflozin in Heart Failure with a Preserved Ejection Fraction I October 14, 2021
• Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure I September 28, 2021
• Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial I March 23, 2021
• Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction I January 26, 2021

• Dapagliflozin in Patients Recently Hospitalized with Heart Failure and Mildly Reduced and Preserved Ejection Fraction | September 26, 2022
• What to Expect From the 2022 HF Guidelines I May 17, 2022
• In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction I November 8, 2021
• New Hope in HF: The Evolving Evidence for SGLT2 Inhibitors I July 30, 2021 
• SGLT2 Inhibitors in HF: New Treatment for an Old Disease I October 13, 2020
• How Do You Integrate the Use of GLP-1 RAs and SGLT2 Inhibitors Into Your Health Care Setting in a Multidisciplinary Way? I August 03, 2020
• The Intersection of CVD and Type 2 Diabetes: The Role of SGLT2 Inhibitors and GLP-1 RAs in Cardiology I May 18, 2020

• Empagliflozin in Patients Hospitalized for Acute Heart Failure - EMPULSE
• Empagliflozin in Non-diabetic Heart Failure Patients With Reduced Ejection Fraction - EMPATROPISM
• Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction - EMPEROR-Preserved
• Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction - EMPEROR-Reduced
• Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - DAPA-HF
• Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure - DELIVER

• SGLT2 Inhibitors in HFrEF
• Untreated HFrEF / Ischemic Cardiomyopathy in Type 2 DM – How to Optimize Medical Therapy to Improve Heart Failure Outcomes
• Unrecognized HFpEF in a Type 2 DM Patient - Reducing CV and HF Risk
• Improving Outcomes for Patients with HFrEF and T2DM
• Management of CKD in a Patient with Cardiovascular Disease

• What's New in HF Pharmacotherapies: The What, How, and Wow
• SGLT2is: The New Pillar in Heart Failure Care - Clinical Spotlight Series Meeting on Demand
• Heart Failure SAP
• Deciphering SGLT2's: Mechanisms of Action and Resulting Indications
• The Findings: Navigating the SGLT2s Clinical Trials

We are grateful to these distinguished faculty who contributed to this collection:

Alison Bailey, MD, FACC (Chair) 

James L. Januzzi, Jr., MD, FACC (Chair)

Educational Grant Support Provided By: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) and Lilly USA, LLC (Lilly)

Page Launched: December 2022